Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 10
Journal homepage
10
Views
1
CrossRef citations to date
0
Altmetric
Anticancers, Hormonals & Metabolic Disease Therapy

Overview: Macrocyclic Chelators as Anticancer Agents in Radioimmunotherapy

Nigel R A Beeley Celltech Ltd, 216 Bath Road, Slough, SL1 4EN, UK
&
Phillip R J Ansell Celltech Ltd, 216 Bath Road, Slough, SL1 4EN, UK
Pages 1539-1553 | Published online: 02 Mar 2011

References to Primary Literature

  • Hollstein, U Nonlactam antibiotics Burger's Medicinal Chemistry, 4th Edition Wolff, ME 1979 Part II 173–288.
  • Fajer, J The mysteries of porphyrin chemistry. Chem. Ind. 1991 869–873.
  • Monoclonal antibodies. Epenetos, AA Chapman and Hall London 1991.
  • May, PM Agents acting on passive ion transport Comprehensive Medicinal Chemistry Sammes, PE, Taylor, JB 1990 2 175–192.
  • Dougherty, TJ Photosensitizers: Therapy and detection of malignant tumours. Photochem. Photobiol. 1987 45 879–889.
  • Bonnett, R A death ray for cancer. New Scientist 1989 55–58.
  • Beierwaltes, WH Radioimmunotherapy of cancer: Historical perspectives and prospects for the future Radiolabelled Monoclonal Antibodies for Imaging and Therapy. Srivastava, SC NATO ASI Series Series A: Life Sciences 1988 152 739–768.
  • Kohler, G Milstein, C Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975 256 495–497.
  • Boyer, CM Lidor, Y Lottich, SC Bast, RC Jr Antigenic cell surface markers in human solid tumours. Antibody, Immunoconjugates and Radiopharmaceuticals 1988 1 105–162.
  • Hinman, LM Wallace, RE Hamann, PR Durr, FE Upeslacis, J Calicheamicin Immunoconjugates: Influence of analog and linker modification on activity in vivo. Antibody, Immunoconjugates and Radiopharmaceuticals 1990 3 59.
  • Buchsbaum, DJ Lawrence, TS Tumour therapy with radiolabelled monoclonal antibodies. Antibody, Immunoconjugates and Radiopharmaceuticals 1991 4 245–272.
  • Humm, JL Chin, LM Review of experimental methods to determine radiation absorbed dose in radioimmunotherapy. Antibody, Immunoconjugates and Radiopharmaceuticals 1991 4 613–621.
  • Davidson, BR Waddington, WA Short, MD Boulos, PB Intraoperative localisation of colorectal cancers using radiolabelled monoclonal antibodies. Br. J. Surg. 1991 78 664–670.
  • Parker, D Tumour targeting. Chem. Brit. 1990 942–945.
  • Troutner, DE Simon, J Ketring, AR Volkert, W Holmes, RA Complexing of 99mTc with cyclam. J. Nucl. Med. 1980 21 443–448.
  • Morphy, JR Parker, D Alexander, R Bains, A Carne, AF Eaton, MAW Harrison, A Millican, A Phipps, A Rhind, SK Titmas, R Weatherby, D Antibody labelling with functionalised cyclam macrocycles. J. Chem. Soc., Chem. Comm. 1988 156–158.
  • Adair, JR Baker, TS Bebbington, CR Beeley, NRA Emtage, JS King, DJ Lawson, ADG Millican, TA Mountain, A Owens, RJ Yarranton, GT Engineering monoclonal antibody B72.3 for cancer therapy. Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. Clark, MR 1992 In Press.
  • Rhind, SK Harrison, A Walker, C Morphy, JR Millican, TA Weatherby, D Boden, J Pedley, RB Searle, FA Begent, RHJ Bagshawe, KD Eaton, MAW Parker, D In vivo stability of 99mTc macrocycle-B72.3 immunoconjugate. Antibody, Immunoconjugates and Radiopharmaceuticals 1990 3 55.
  • Schwarz, A Steinstraesser, A A novel approach to 99mTc labelled monoclonal antibodies. J. Nucl. Med. 1987 28 721.
  • Carrasquillo, JA Krohn, KA Beaumier, P McGuffin, RW Brown, JP Hellstrom, KE Hellstrom, I Larson, SM Diagnosis of and therapy for solid tumours with radiolabelled antibodies and immune fragments. Cancer Treat. Rep. 1984 68 317–328.
  • Kasina, S Rao, TN Srinivasan, A Sanderson, JA Fitzner, JN Reno, JM Beaumier, PL Fritzberg, AR Development and biologic evaluation of a kit for preformed chelate 99mTc radiolabelling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J. Nucl. Med. 1991 32 1445–1451.
  • Hnatowich, D Layne, WW Childs, RL Lanteigne, D Davis, MA Griffin, TW Doherty, PW Radiolabelling of antibody: A simple and efficient method. Science 1983 220 613–615.
  • Hnatowich, DF Griffin, TW Kosciuczyk, C Rusckowski, M Childs, RL Mattis, JA Shealy, D Doherty, PW Pharmacokinetics of an 111In labelled monoclonal antibody in cancer patients. J. Nucl. Med. 1985 26 849–858.
  • Broan, CJ Cox, JPL Craig, AS Kataky, R Parker, D Harrison, A Taylor, M Ferguson, G Structure and solution stability of indium and gallium complexes of NOTA and yttrium complexes of DOTA and related ligands: Kinetically stable complexes for use in imaging and radioimmunotherapy. J. Chem. Soc. Perkin II 1991 87–89.
  • Craig, AS Parker, D Adams, H Bailey, NA Stability, 71Ga NMR and crystal structure of a neutral gallium(III) complex of 1,4,7-triazacyclononanetriacetate: A potential radiopharmaceutical? J. Chem. Soc. Chem. Comm. 1989 1793–1794.
  • Craig, AS Helps, IM Jankowski, KJ Parker, D Beeley, NRA Boyce, BA Eaton, MAW Millican, AT Millar, K Phipps, A Rhind, SK Harrison, A Walker, C Towards tumour imaging with indium-111 labelled macrocycle-antibody conjugates. J. Chem. Soc. Chem. Comm. 1989 794–796.
  • Rhind, SK Phipps, A Pedley, RB Boden, J Green, AJ King, DJ Millican, AT Millar, K Boyce, BA Beeley, NRA Eaton, MAW Begent, RHJ Bagshawe, KD Secher, DS Parker, D Tumour imaging with indium-111 macrocycle chimeric B72.3(γ4) antibody conjugates. 5th International Conference on Monoclonal Antibody Immunoconjugates for Cancer San Diego, USA March 15–17 1990.
  • Celltech Ltd Unpublished observations.
  • Granowska, M Mather, SJ Britton, KE Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: Correlations with surgery. Nucl. Med. Biol. 1991 18 413–424.
  • Broan, CJ Jankowski, KJ Kataky, R Parker, D Synthesis and complex stability of parent and C-functionalised derivatives of 1,4,7-triazacyclononane-1,4,7-tris[methylene(methylphosphinic acid)]: An effective new complexing agent. J. Chem. Soc. Chem. Comm. 1990 1738–1739.
  • Wessels, BW Rogus, RD Radionuclide selection and model absorbed dose calculations for radiolabelled tumour associated antibodies. Med. Phys. 1984 11 638–645.
  • Adelstein, SJ Kassis, AI Criteria for the selection of radionuclides for radioimmunotherapy Radiolabelled Monoclonal Antibodies for Imaging and Therapy. Srivastava, SC NATO ASI Series Series A: Life Sciences 1988 152 165–176.
  • Gansow, OA Brechbiel, MW Pippin, CG McMurry, TJ Lambrecht, R Colcher, D Schlom, J Roselli, M Strand, M Huneke, RB Ruegg, CL Lead and bismuth complexes of functionalised DTPA ligands and of the polyazacycloalkane-N-acetic acid DOTA. Utility for radioimmunoimaging and radioimmunotherapy. Antibody, Immunoconjugates and Radiopharmaceuticals 1991 4 413–425.
  • Kumar, K Magerstadt, M Gansow, OA Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids NOTA, DOTA and TETA. J. Chem. Soc. Chem. Comm. 1989 145–146.
  • Ruegg, CL Anderson-Berg, WT Brechbiel, MW Mirzadeh, S Gansow, OA Strand, M Improved in vivo stability and tumor targeting of bismuth-labelled antibody. Cancer Res. 1990 50 4221–4226.
  • Sharkey, RM Kaltovich, FA Shih, LB Fand, I Govelitz, G Goldenberg, DM Radioimmunotherapy of human colonic cancer xenografts with 90Y labelled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 1988 48 3270–3275.
  • Hnatowich, DJ Chinol, M Siebecker, DA Gionet, M Griffin, T Doherty, PW Hunter, R Kase, KR Patient biodistribution of intra-peritoneally administered 90Y labelled antibody. J. Nucl. Med. 1988 29 1428–1434.
  • Cox, JPL Jankowski, KJ Kataky, R Parker, D Beeley, NRA Boyce, BA Eaton, MAW Millican, AT Millar, K Harrison, A Walker, C Synthesis of a kinetically stable yttrium-90 labelled macrocycle-antibody conjugate. J. Chem. Soc. Chem. Comm. 1989 797–798.
  • Cox, JPL Craig, AS Helps, IM Jankowski, KJ Parker, D Eaton, MAW Millican, AT Millar, K Beeley, NRA Bocye, BA Synthesis of C- and N-functionalised derivatives of NOTA, DOTA and DTPA: Bifunctional complexing agents for the derivatisation of antibodies. J. Chem. Soc. Perkin. I 1990 2567–2576.
  • Harrison, A Walker, CA Parker, D Jankowski, KJ Cox, JPL Craig, AS Randall, AM Sansom, JM Eaton, MAW Beeley, NRA Millican, AT Millar, K Boyce, BA Rhind, SK Turner, A Farnsworth, A The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl. Med. Biol. 1991 18 469–476.
  • Farnsworth, A Turner, A Rhind, SK Millican, AT Millar, K Boyce, BA Beeley, NRA Boden, J Boden, R Pedley, RB Parker, D Comparative biodistributions of 90Y and 111In macrocycle chimeric B72.3 conjugates in a human colon carcinoma xenograft model. J. Nucl. Med. 1991 32 1842.
  • Moi, MK Meares, CF Denardo, SJ The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N″,N'″-tetraacetic acid and study of its yttrium (III) complex. J. Amer. Chem. Soc. 1988 110 6266–6267.
  • Snook, DE Rowlinson-Busza, G Meares, C Epenetos, AA Indium-111 and yttrium-90 labelled macrocyclic chelating agents Monoclonal antibodies. Epenetos, AA Chapman and Hall London 1991 157–166.
  • Hird, V Snook, D Kosmas, C Dhokia, B Stewart, S Mason, P Lambert, J Meares, C Epenetos, AA Intra-peritoneal radioimmunotherapy with yttrium-90 labelled immunoconjugates Monoclonal antibodies. Epenetos, AA Chapman and Hall London 1991 267–271.
  • Hird, V Verhoeyen, M Badley, RA Price, D Snook, D Kosmas, C Gooden, C Bamias, A Meares, C Lavender, JP Epenetos, AA Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. Br. J. Cancer 1991 64 911–914.
  • Kosmas, C Snook, D Gooden, CS Courtenay-Luck, NS McCall, MJ Meares, CF Epenetos, AA Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugate for imaging and therapy. Cancer Res. 1992 52 904–911.
  • Kabachnik, IM Medved', TY Bel'skii, FI Pisareva, SA Synthesis, acid-base and complex forming properties of 1,4,7,10-tetrakis (dihydroxyphosphorylmethyl)-1,4,7,10-tetraazacyclododecane. Izv. Akad. Nauk. SSSR Ser. Khim. 1984 844–849.
  • Broan, CJ Cole, E Jankowski, KJ Parker, D Pulukoddy, K Boyce, BA Beeley, NRA Millar, K Millican, AT Synthesis of new macrocyclic amino-phosphinic acid complexing agents and their C- and P-functionalised derivatives for protein linkage. Synthesis 1992 63–68.
  • Beeley, NRA Boyce, BA Eaton, MAW Farnsworth, A Howat, D Millar, K Millican, AT Rhind, SK Secher, D Turner, A Harrison, A Randall, A Walker, C Begent, RHJ Boden, J Boden, R Pedley, RB Broan, C Jankowski, K Kataky, R Parker, D Novel phosphinate macrocycles: Bone localisation of 90Y-12N4P4-cB72.3 conjugates 6th International Conference on Monoclonal Antibody Immunoconjugates for Cancer San Diego, USA 1991 28 February-2 March.
  • Meares, CF Diril, H Kukis, D McCall, M Rana, T Wellman, A DeNardo, SJ DeNardo, GL Radiochemistry of antibodies: Some recent advances. Antibody, Immunoconjugates and Radiopharmaceuticals 1991 4 389–398.
  • Morphy, JR Parker, D Kataky, R Harrison, A Eaton, MAW Millican, A Phipps, A Walker, C Towards tumour targeting with copper radiolabelled macrocycle-antibody conjugates. J. Chem. Soc. Chem. Comm. 1989 792–794.
  • Meares, CF Studer, M Diril, H Kukis, DL Preparation and characterisation of new bifunctional chelating agents for copper-67. J. Nucl. Med. 1992 33 942.
  • Kukis, DL DeNardo, SJ DeNardo, GL Diril, H McCall, MJ Meares, CF Radiolabelling of antibody-macrocycle chelate conjugates. J. Nucl. Med. 1992 33 1031.
  • King, DJ Mountain, A Adair, JR Owens, RJ Harvey, A Weir, N Proudfoot, KA Phipps, A Lawson, A Rhind, SK Pedley, B Boden, J Boden, R Begent, RHJ Yarranton, GT Tumour localisation of engineered antibody fragments. Antibody, Immunoconjugates and Radiopharmaceuticals 1992 5 159–170.
  • Meredith, RF Khazaeli, MB Plott, WE Brezovich, IA Russell, CD Wheeler, RH Spencer, SA LoBuglio, AF Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer. Antibody, Immunoconjugates and Radiopharmaceuticals 1992 5 75–80.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.